Liraglutide
GLP-1-analoog; 60 kg per jaar uit een fermentatietank van 1.000 L.
A GLP-1 analogue that raises insulin release and lowers glucagon in a glucose-dependent way, slows gastric emptying and reduces appetite. Made by fermentation and semi-synthesis: high solubility, low aggregation, high in-vitro activity.
Chemische identiteit
- CAS-nummer
- 204656-20-2
- Molecuulgewicht
- 3751 g/mol
- InChIKey
- YSDQQAXHVYUZIW-QCIJIYAXSA-N
- PubChem CID
- 16134956
Specificatie
| Made by | Fermentatie met E. coli en semisynthese |
| Peptide map | Identiek aan de referentie (batchresultaat: voldoet) |
| Hydrophilic impurities | ≤ 2,5 % (batchresultaat: 0,4 %) |
| Hydrophobic impurities | ≤ 0,5 % (batchresultaat: 0,2 %) |
| Total impurities | ≤ 5,2 % (batchresultaat: 1,4 %) |
| High-molecular-weight proteins | ≤ 0,7 % (batchresultaat: 0,04 %) |
| Bioburden | < 100 cfu/g (batchresultaat: voldoet) |
| Bacterial endotoxin | < 10 EU/mg (batchresultaat: voldoet) |
| Host cell protein | < 100 ng/mg (batchresultaat: voldoet) |
| Ethanol | ≤ 5.000 ppm (batchresultaat: 54 ppm) |
| Acetonitrile | ≤ 410 ppm (batchresultaat: 55 ppm) |
| Triethylamine | ≤ 5.000 ppm (batchresultaat: niet aangetoond) |

- Fermentatietank van 1.000 L, 60 kg per jaar.
- Stability studies and support for a DMF application.

